14638334

Source:http://linkedlifedata.com/resource/pubmed/id/14638334

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013557, umls-concept:C0035525, umls-concept:C0087111, umls-concept:C0205210, umls-concept:C0205265, umls-concept:C0439831, umls-concept:C0521026, umls-concept:C0524910, umls-concept:C0796545, umls-concept:C0871261, umls-concept:C1280500, umls-concept:C1555582, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:issue	11
pubmed:dateCreated	2003-11-25
pubmed:abstractText	Evaluation of 12-wk viral response to initial antiviral therapy for chronic hepatitis C has been recommended to minimize antiviral-associated morbidity and costs. The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during antiviral therapy for treatment naive chronic hepatitis C patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0421030
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0002-9270
pubmed:author	pubmed-author:AlbrechtJanice KJK, pubmed-author:DavisGary LGL, pubmed-author:International Hepatitis Interventional Therapy Group, pubmed-author:MannsMichael PMP, pubmed-author:McHutchisonJohn GJG, pubmed-author:WongJohn BJB
pubmed:issnType	Print
pubmed:volume	98
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2354-62
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:14638334-Cost-Benefit Analysis, pubmed-meshheading:14638334-Dose-Response Relationship, Drug, pubmed-meshheading:14638334-Drug Administration Schedule, pubmed-meshheading:14638334-Drug Therapy, Combination, pubmed-meshheading:14638334-Evaluation Studies as Topic, pubmed-meshheading:14638334-Female, pubmed-meshheading:14638334-Hepacivirus, pubmed-meshheading:14638334-Hepatitis C, Chronic, pubmed-meshheading:14638334-Humans, pubmed-meshheading:14638334-Interferon-alpha, pubmed-meshheading:14638334-Male, pubmed-meshheading:14638334-Polyethylene Glycols, pubmed-meshheading:14638334-Polymerase Chain Reaction, pubmed-meshheading:14638334-Quality-Adjusted Life Years, pubmed-meshheading:14638334-Recombinant Proteins, pubmed-meshheading:14638334-Ribavirin, pubmed-meshheading:14638334-Survival Analysis, pubmed-meshheading:14638334-Treatment Outcome, pubmed-meshheading:14638334-Viral Load
pubmed:year	2003
pubmed:articleTitle	Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
pubmed:affiliation	Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study